Blogs

The new Executive Director of the EMA has managed to stay calm under financial and political pressure.

European Forum for Good Clinical Practice meeting on informed consent draws a huge crowd.

Europe's struggling economies may have unexpected effects on the pharmaceutical sector.

The management board has a supervisory role with general responsibility for budgetary and planning matters, the appointment of the Executive Director, and the monitoring of the Agency's performance.

The Innovative Medicines Initative has launched several projects to improve quality of life.

EU's new rules will be influenced by more than just those primarily responsible for pharmaceuticals.

EU's new rules will be influenced by more than just those primarily responsible for pharmaceuticals.

A meeting in July to discuss changes to the old rules explored the need for compromise across the industry.

A newly released report has the pharma industry facing some new rivals.

A potential solution for many, personalized medicine still faces economic, regulatory, and cultural challenges.

Europe aism to increase jobs and growth through its "Europe 2020" strategy.

March marked a busy month for the UE with guidance updates and the launch of new medicine research.

The European Union is accepting input regarding changes to the directive until the end of May.

Renewed pandemic fears drawn the sting from criticisms of industry and regulators.

An alliance between two European leaders gives hope for unison but falls short on solutions.

The management board has a supervisory role with general responsibility for budgetary and planning matters, the appointment of the Executive Director, and the monitoring of the Agency's performance.

The European Medicines Agency responds to concerns over conflict of interest and openness.

Routine inspections and regulations can help maintain GCP standards in global trials.

The NICE will possess greater power, scope, and status under the new system.

European network could bring confusion to health technology assessment and clinical research.

The verdict is awaited on the much criticized and long anticipated European clinical trials directive.

New guidelines are being developed in Europe to address questions regarding stem-cell medicines.